Teva & Norton v. Cipla: QVAR RediHaler Patent Dispute Consolidated in NJ
Teva Pharmaceutical Industries and Norton (Waterford) Limited filed suit against Cipla Limited in the District of New Jersey, asserting US11957832B2 against Cipla’s generic version of the QVAR RediHaler (beclomethasone dipropionate, 40 mcg). The case was consolidated with related proceedings after 273 days, a resolution pathway common in multi-front ANDA litigation.
Filing to Case Consolidated in 273 days
273 days — typical for a Hatch-Waxman consolidation before full discovery commences
Case consolidated: what the transfer to a unified docket means for both parties
Consolidation joins parallel Hatch-Waxman cases into one proceeding
When multiple related ANDA patent cases share common patents, products, or parties, federal courts routinely consolidate them under one docket. This avoids duplicative discovery, inconsistent rulings, and judicial inefficiency. Consolidation does not resolve the underlying infringement dispute — it restructures where and how it is litigated. The ESI protocol stipulated here suggests active discovery coordination was already underway before consolidation was ordered.
Procedural — no merits rulingPatent exclusivity claims survive and continue in consolidated forum
For Teva and Norton, consolidation is neither a win nor a loss on the merits. Their infringement claims under US11957832B2 remain live. Consolidation may, however, streamline their litigation burden if they are simultaneously asserting the same patent against other generic filers. The 30-month stay protections typical in Hatch-Waxman actions may remain operative depending on filing timelines.
Claims remain activeCipla’s invalidity and non-infringement defences carry forward
Cipla Limited and its US affiliate face continued exposure under the consolidated docket. No judgment, consent decree, or licence has been disclosed in the public record of this individual case. Consolidation may benefit Cipla if it aligns its defence with other generics asserting similar invalidity arguments against US11957832B2, potentially sharing discovery and expert costs across the consolidated proceedings.
Defence continues in new docketQVAR RediHaler generic market entry remains uncertain pending consolidated outcome
Beclomethasone dipropionate inhalers represent a meaningful respiratory market segment. Until the consolidated litigation resolves — whether by settlement, consent decree, or court judgment — Cipla’s generic entry is subject to continued delay. Competing generic filers facing the same patent landscape will be directly affected by the consolidated proceedings’ outcome, making this a closely watched docket for the inhaled corticosteroid sector.
Generic entry timing uncertainFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Teva Pharmaceutical Industries, Ltd. | Company | Search in Eureka ↗ |
| Co-Plaintiff | Norton (Waterford) Limited | Individual | Search in Eureka ↗ |
| Defendant | Cipla Limited | Individual | Search in Eureka ↗ |
| Plaintiff counsel | Christine Clark | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Hector Daniel Ruiz | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Liza M. Walsh | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Selena Miriam Ellis | Attorney | Counsel for Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Plaintiff law firm | DEMANT | Law Firm | Representing Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Plaintiff law firm | Walsh Pizzi O’reilly Falanga, LLP | Law Firm | Representing Teva Pharmaceutical Industries, Ltd.Search in Eureka ↗ |
| Defendant counsel | Loly G. Tor | Attorney | Counsel for Cipla LimitedSearch in Eureka ↗ |
| Defendant law firm | K&L Gates LLP | Law Firm | Representing Cipla LimitedSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | New Jersey District CourtSearch in Eureka ↗ |
Official order — verbatim text
The docket’s termination record reflects a procedural consolidation, not a merits adjudication. The stipulated ESI order entered before consolidation confirms both sides were engaged in substantive discovery preparation. No infringement finding, invalidity ruling, or consent decree was entered in this individual case. The consolidated docket inherits all pending claims and defences, and the public record of this case number is silent on any licensing terms or settlement conditions between Teva, Norton, and Cipla.
US11957832B2 — beclomethasone dipropionate inhalation aerosol technology
US11957832B2 (application number US17/062185) protects formulations and delivery technology underlying the QVAR RediHaler, an inhaled corticosteroid product delivering beclomethasone dipropionate at 40 mcg per actuation. Beclomethasone dipropionate is a well-established corticosteroid used in the management of asthma; the patent’s value lies in the specific formulation, device interface, or delivery characteristics that differentiate the RediHaler presentation from earlier beclomethasone products.
For Teva and Norton, US11957832B2 represents a line of defence against generic substitution in a mature but commercially significant inhaled corticosteroid segment. Any generic filer referencing QVAR RediHaler as the reference listed drug must contend with this patent through Paragraph IV certification or design-around. The outcome of the consolidated proceedings will determine whether this patent functions as an effective exclusivity extender or whether its claims are vulnerable to prior art or non-infringement arguments that open the market to generic entry.
Should your inhaler product run an FTO against US11957832B2?
Any company developing, manufacturing, or commercialising a beclomethasone dipropionate inhalation aerosol — whether a generic ANDA filer, a branded line extension, or a device technology partner — should assess freedom-to-operate against US11957832B2. The active Hatch-Waxman enforcement by Teva and Norton demonstrates this patent is being asserted aggressively. R&D teams formulating pressurised metered-dose or breath-actuated inhalers in the corticosteroid space are particularly exposed if their product parameters overlap with the granted claims.
PatSnap Eureka’s FTO Search Agent can map the claim landscape of US11957832B2 against your product specifications, identify potential design-around pathways, and flag prosecution history estoppel that may limit or expand claim scope. Eureka also surfaces related continuation and divisional applications in Teva and Norton’s portfolio that may present additional freedom-to-operate considerations — giving your IP and R&D teams a complete picture before advancing to clinical or commercial development stages.
Run a freedom-to-operate analysis on US11957832B2 to assess your product’s exposure
Run FTO in Eureka →Similar Hatch-Waxman inhaler patent cases in US District Courts
Explore related Hatch-Waxman infringement actions involving inhaled corticosteroid patents litigated in New Jersey and Delaware federal district courts.
What this case signals for the inhaled corticosteroid IP landscape
Teva’s enforcement of US11957832B2 against Cipla reflects broader Hatch-Waxman dynamics in the branded inhaler market.
Consolidation signals multiple generic challengers in the QVAR RediHaler space
Courts consolidate Hatch-Waxman cases when several ANDAs target the same branded product. The consolidation here suggests Cipla is not the only generic filer — other challengers may be litigating the same patent in parallel, increasing the stakes of the ultimate ruling on US11957832B2 for the entire beclomethasone dipropionate market.
ESI protocol activity before consolidation indicates substantial discovery preparation
The parties had already negotiated and filed an ESI protocol — a resource-intensive early-stage step — before this docket was consolidated. This signals that both sides were preparing for full merits litigation, not an early exit. Generic entrants and branded competitors alike should monitor the consolidated case closely for claim construction and expert schedules.
Teva v Cipla — key questions answered
Case 2:24-cv-07162 is a Hatch-Waxman patent infringement action filed by Teva Pharmaceutical Industries and Norton (Waterford) Limited against Cipla Limited in the District of New Jersey. The plaintiffs assert US11957832B2 against Cipla’s generic version of the QVAR RediHaler (beclomethasone dipropionate, 40 mcg). The case was consolidated with related proceedings after 273 days, with no merits ruling entered on this individual docket.
Consolidation means this individual case was merged into a unified docket with one or more related cases sharing common patents, parties, or products. The underlying infringement claims against Cipla are not dismissed or resolved — they continue in the consolidated proceeding. This is a procedural outcome, not a substantive ruling on patent validity or infringement of US11957832B2.
Teva and Norton assert US11957832B2 (application US17/062185) against Cipla’s generic beclomethasone dipropionate, 40 mcg inhalation aerosol product, which references the branded QVAR RediHaler as its reference listed drug. The patent relates to formulation and delivery technology for beclomethasone dipropionate pressurised inhalers.
The ESI protocol was negotiated pursuant to the court’s Amended Scheduling Order, which required the parties to agree on electronic discovery terms by September 30, 2024. This is a standard early-stage litigation step in complex patent cases. Its filing before consolidation indicates both sides were preparing for substantive discovery, and the protocol likely carries forward into the consolidated proceedings.
Teva Pharmaceutical Industries and Norton (Waterford) are represented by Walsh Pizzi O’Reilly Falanga LLP and the DEMANT firm, with attorneys including Liza M. Walsh, Christine Clark, Hector Daniel Ruiz, and Selena Miriam Ellis. Cipla Limited is represented by K&L Gates LLP, with Loly G. Tor listed as counsel of record.
PatSnap Eureka searches patents and litigation data to answer instantly.